MX2020011826A - Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. - Google Patents
Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.Info
- Publication number
- MX2020011826A MX2020011826A MX2020011826A MX2020011826A MX2020011826A MX 2020011826 A MX2020011826 A MX 2020011826A MX 2020011826 A MX2020011826 A MX 2020011826A MX 2020011826 A MX2020011826 A MX 2020011826A MX 2020011826 A MX2020011826 A MX 2020011826A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- bisfluoroalkyl
- combination compositions
- benzodiazepinone compounds
- compounds
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012830 cancer therapeutic Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667540P | 2018-05-06 | 2018-05-06 | |
| PCT/US2019/030771 WO2019217250A1 (en) | 2018-05-06 | 2019-05-05 | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011826A true MX2020011826A (es) | 2021-01-15 |
Family
ID=68468208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011826A MX2020011826A (es) | 2018-05-06 | 2019-05-05 | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210244745A1 (https=) |
| EP (1) | EP3790552A4 (https=) |
| JP (1) | JP7522661B2 (https=) |
| KR (1) | KR20210005714A (https=) |
| CN (1) | CN112218639A (https=) |
| AU (2) | AU2019266150A1 (https=) |
| BR (1) | BR112020022654A2 (https=) |
| CA (1) | CA3099479A1 (https=) |
| IL (1) | IL278492B2 (https=) |
| MX (1) | MX2020011826A (https=) |
| SG (1) | SG11202011041YA (https=) |
| WO (1) | WO2019217250A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022241095A1 (en) * | 2021-05-13 | 2022-11-17 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating cancer |
| US20220339162A1 (en) * | 2018-05-06 | 2022-10-27 | Ayala Pharmaceuticals Inc. | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating desmoid tumors |
| WO2019215585A1 (en) * | 2018-05-06 | 2019-11-14 | Ayala Pharmaceuticals Inc. | Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| CN118750499A (zh) | 2018-05-15 | 2024-10-11 | 艾雅拉制药公司 | 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物 |
| SG11202011589WA (en) * | 2018-05-24 | 2020-12-30 | Ayala Pharmaceuticals Inc | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof |
| SG11202112061RA (en) * | 2019-05-15 | 2021-11-29 | Ayala Pharmaceuticals Inc | Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer |
| EP4337204A4 (en) * | 2021-05-13 | 2025-04-16 | Ayala Pharmaceuticals Inc. | COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF CANCER |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| US20140357605A1 (en) * | 2012-03-22 | 2014-12-04 | Bristol-Myers Squibb Company | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| US9763956B2 (en) | 2012-06-19 | 2017-09-19 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| WO2014047391A1 (en) * | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
| TWI614238B (zh) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| WO2014165718A1 (en) * | 2013-04-04 | 2014-10-09 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
| WO2015082583A1 (en) * | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| WO2016070051A2 (en) * | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| ES3057783T3 (en) * | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| ES2881801T3 (es) | 2016-04-12 | 2021-11-30 | Lilly Co Eli | Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón |
| US20190185559A1 (en) * | 2016-09-02 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| IL268349B2 (en) * | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| WO2018201056A1 (en) * | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
-
2019
- 2019-05-05 CA CA3099479A patent/CA3099479A1/en active Pending
- 2019-05-05 KR KR1020207034548A patent/KR20210005714A/ko not_active Ceased
- 2019-05-05 WO PCT/US2019/030771 patent/WO2019217250A1/en not_active Ceased
- 2019-05-05 CN CN201980036073.7A patent/CN112218639A/zh active Pending
- 2019-05-05 JP JP2020563505A patent/JP7522661B2/ja active Active
- 2019-05-05 MX MX2020011826A patent/MX2020011826A/es unknown
- 2019-05-05 US US17/052,812 patent/US20210244745A1/en not_active Abandoned
- 2019-05-05 AU AU2019266150A patent/AU2019266150A1/en not_active Abandoned
- 2019-05-05 BR BR112020022654-8A patent/BR112020022654A2/pt not_active Application Discontinuation
- 2019-05-05 SG SG11202011041YA patent/SG11202011041YA/en unknown
- 2019-05-05 IL IL278492A patent/IL278492B2/en unknown
- 2019-05-05 EP EP19800442.6A patent/EP3790552A4/en not_active Withdrawn
-
2020
- 2020-10-22 US US17/077,857 patent/US12281085B2/en active Active
-
2025
- 2025-03-07 AU AU2025201674A patent/AU2025201674A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL278492A (https=) | 2021-01-31 |
| IL278492B2 (en) | 2025-03-01 |
| SG11202011041YA (en) | 2020-12-30 |
| CN112218639A (zh) | 2021-01-12 |
| AU2019266150A1 (en) | 2021-01-07 |
| KR20210005714A (ko) | 2021-01-14 |
| US20210244745A1 (en) | 2021-08-12 |
| EP3790552A1 (en) | 2021-03-17 |
| EP3790552A4 (en) | 2022-06-15 |
| AU2025201674A1 (en) | 2025-03-27 |
| JP7522661B2 (ja) | 2024-07-25 |
| CA3099479A1 (en) | 2019-11-14 |
| BR112020022654A2 (pt) | 2021-03-09 |
| US20210040050A1 (en) | 2021-02-11 |
| JP2021523169A (ja) | 2021-09-02 |
| US12281085B2 (en) | 2025-04-22 |
| WO2019217250A1 (en) | 2019-11-14 |
| IL278492B1 (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230272A1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| JOP20230318A1 (ar) | مشتقات تترا هيدرو – إيميدازوبيريدين كمعدِّلات مناعية pd-l1 | |
| MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| JOP20200315A1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| MX390535B (es) | Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer. | |
| MX2020010469A (es) | Inhibidores del atf6 y sus usos. | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 |